UPDATE: Oppenheimer Upgrades Mead Johnson Nutrition on China Child Policy Tailwind to Infant Formula Industry

In a report published Tuesday, Oppenheimer analyst Ingrid Yin upgraded the rating on Mead Johnson Nutrition Co. (NYSE: MJN ) from Perform to Outperform, and named a $100.00 price target. In the report, Oppenheimer noted, “Recently China announced further loosening of the ‘One-Child Policy,' allowing people to have two babies